These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

616 related items for PubMed ID: 16944964

  • 1. Cardiovascular safety profiles of aromatase inhibitors : a comparative review.
    Nabholtz JM, Gligorov J.
    Drug Saf; 2006; 29(9):785-801. PubMed ID: 16944964
    [Abstract] [Full Text] [Related]

  • 2. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [Abstract] [Full Text] [Related]

  • 3. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M.
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [Abstract] [Full Text] [Related]

  • 4. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J.
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [Abstract] [Full Text] [Related]

  • 5. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P, Frassoldati A.
    Breast J; 2007 Nov; 13(1):28-35. PubMed ID: 17214790
    [Abstract] [Full Text] [Related]

  • 6. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F, GIM Investigators.
    Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
    [Abstract] [Full Text] [Related]

  • 7. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    Mouridsen HT, Robert NJ.
    MedGenMed; 2005 Aug 24; 7(3):20. PubMed ID: 16369246
    [Abstract] [Full Text] [Related]

  • 8. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE.
    Am J Clin Oncol; 2003 Aug 24; 26(4):S27-33. PubMed ID: 12902874
    [Abstract] [Full Text] [Related]

  • 9. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS.
    Ann Oncol; 2008 Jan 24; 19(1):16-27. PubMed ID: 17693420
    [Abstract] [Full Text] [Related]

  • 10. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ.
    Oncology; 2005 Jan 24; 69(1):1-9. PubMed ID: 16088229
    [Abstract] [Full Text] [Related]

  • 11. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
    Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P.
    Curr Med Res Opin; 2006 Aug 24; 22(8):1575-85. PubMed ID: 16870082
    [Abstract] [Full Text] [Related]

  • 12. The use of aromatase inhibitors in adjuvant therapy for early breast cancer.
    Jonat W, Hilpert F, Maass N.
    Cancer Chemother Pharmacol; 2005 Nov 24; 56 Suppl 1():32-8. PubMed ID: 16273366
    [Abstract] [Full Text] [Related]

  • 13. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU, Cuzick J.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [Abstract] [Full Text] [Related]

  • 14. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
    Ingle JN.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
    [Abstract] [Full Text] [Related]

  • 15. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G.
    Cancer; 2004 Oct 01; 101(7):1482-9. PubMed ID: 15378476
    [Abstract] [Full Text] [Related]

  • 16. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J, ABCSG and the GABG.
    Lancet; 2004 Oct 01; 366(9484):455-62. PubMed ID: 16084253
    [Abstract] [Full Text] [Related]

  • 17. Are aromatase inhibitors superior to antiestrogens?
    Howell A, Buzdar A.
    J Steroid Biochem Mol Biol; 2005 Feb 01; 93(2-5):237-47. PubMed ID: 15860266
    [Abstract] [Full Text] [Related]

  • 18. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT.
    Curr Med Res Opin; 2006 Aug 01; 22(8):1609-21. PubMed ID: 16870085
    [Abstract] [Full Text] [Related]

  • 19. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT, Robert NJ.
    Eur J Cancer; 2005 Aug 01; 41(12):1678-89. PubMed ID: 16098456
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.